Physiomics Plc (PYC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Physiomics Plc (PYC) has a cash flow conversion efficiency ratio of -0.514x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-202.00K ≈ $-24.58 USD) by net assets (GBX393.00K ≈ $47.82 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Physiomics Plc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Physiomics Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Physiomics Plc for a breakdown of total debt and financial obligations.
Physiomics Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Physiomics Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Futura Medical
LSE:FUM
|
1.130x |
|
Sonder Holdings Inc
NASDAQ:SOND
|
0.040x |
|
Premier African Minerals Ltd
LSE:PREM
|
-0.001x |
|
Unicorn Mineral Resources PLC
LSE:UMR
|
N/A |
|
Gaming Technologies Inc. Common Stock
NASDAQ:GMGT
|
0.110x |
|
FAT Brands Inc
NASDAQ:FATBW
|
0.050x |
|
BSF Enterprise Plc
LSE:BSFA
|
-0.102x |
|
Hsin Yung Chien Co Ltd
TW:2114
|
0.010x |
Annual Cash Flow Conversion Efficiency for Physiomics Plc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Physiomics Plc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see Physiomics Plc (PYC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX692.17K ≈ $84.22 |
GBX-546.14K ≈ $-66.45 |
-0.789x | +59.33% |
| 2024-06-30 | GBX282.53K ≈ $34.38 |
GBX-548.13K ≈ $-66.69 |
-1.940x | -289.48% |
| 2023-06-30 | GBX531.72K ≈ $64.69 |
GBX-264.86K ≈ $-32.23 |
-0.498x | -39.03% |
| 2022-06-30 | GBX974.81K ≈ $118.61 |
GBX-349.25K ≈ $-42.49 |
-0.358x | -1185.23% |
| 2021-06-30 | GBX1.17 Million ≈ $141.83 |
GBX-32.50K ≈ $-3.95 |
-0.028x | +68.31% |
| 2020-06-30 | GBX1.31 Million ≈ $160.00 |
GBX-115.69K ≈ $-14.08 |
-0.088x | +62.80% |
| 2019-06-30 | GBX607.91K ≈ $73.97 |
GBX-143.77K ≈ $-17.49 |
-0.237x | +3.89% |
| 2018-06-30 | GBX690.03K ≈ $83.96 |
GBX-169.80K ≈ $-20.66 |
-0.246x | +81.53% |
| 2017-06-30 | GBX328.25K ≈ $39.94 |
GBX-437.27K ≈ $-53.20 |
-1.332x | +21.60% |
| 2016-06-30 | GBX204.15K ≈ $24.84 |
GBX-346.87K ≈ $-42.20 |
-1.699x | -40.90% |
| 2015-06-30 | GBX325.62K ≈ $39.62 |
GBX-392.65K ≈ $-47.77 |
-1.206x | +53.18% |
| 2014-06-30 | GBX136.49K ≈ $16.61 |
GBX-351.51K ≈ $-42.77 |
-2.575x | -25.62% |
| 2013-06-30 | GBX255.82K ≈ $31.13 |
GBX-524.49K ≈ $-63.81 |
-2.050x | -172.94% |
| 2012-06-30 | GBX734.57K ≈ $89.38 |
GBX-551.77K ≈ $-67.13 |
-0.751x | +11.68% |
| 2011-06-30 | GBX756.00K ≈ $91.98 |
GBX-643.00K ≈ $-78.23 |
-0.851x | -54.23% |
| 2010-06-30 | GBX787.00K ≈ $95.76 |
GBX-434.00K ≈ $-52.81 |
-0.551x | -80.29% |
| 2009-06-30 | GBX-85.00K ≈ $-10.34 |
GBX26.00K ≈ $3.16 |
-0.306x | -188.03% |
| 2008-06-30 | GBX-354.00K ≈ $-43.07 |
GBX-123.00K ≈ $-14.97 |
0.347x | +108.89% |
| 2007-06-30 | GBX99.00K ≈ $12.05 |
GBX-387.00K ≈ $-47.09 |
-3.909x | -194.51% |
| 2006-06-30 | GBX-66.00K ≈ $-8.03 |
GBX-273.00K ≈ $-33.22 |
4.136x | +499.14% |
| 2005-06-30 | GBX413.00K ≈ $50.25 |
GBX-428.00K ≈ $-52.08 |
-1.036x | -268.28% |
| 2004-06-30 | GBX-354.00K ≈ $-43.07 |
GBX-218.00K ≈ $-26.52 |
0.616x | -60.87% |
| 2003-06-30 | GBX-129.00K ≈ $-15.70 |
GBX-203.00K ≈ $-24.70 |
1.574x | +233.71% |
| 2001-06-30 | GBX130.00K ≈ $15.82 |
GBX-153.00K ≈ $-18.62 |
-1.177x | -- |
About Physiomics Plc
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more